A National Directory of Drug Treatment Centers and Alcohol Treatment Centers, Therapists and Specialists. A free, simple directory providing assistance and guidance for those seeking help regarding alcohol addiction, drug addiction, dependency and many other conditions that affect the mind, body and soul.
Call 800-580-9104 to speak with an alcohol or drug abuse counselor.

New Medications May Offer Hope to Drinkers Battling Alcohol Dependence

Individuals who experience the physical, mental and social symptoms associated with alcohol dependence are offered hope through the results of two recent studies by researchers at the Medical University of South Carolina (MUSC). In separate investigations, researchers found favorable results for a medication to help heavy drinkers who are trying to modify their consumption, as well as a medication to reduce alcohol withdrawal symptoms and prevent relapse.

In a landmark study, MUSC researchers working with investigators at the University of Virginia Health System and elsewhere have found that topiramate, an effective therapeutic medication, not only decreases heavy drinking, but it also lowers all liver enzymes, plasma cholesterol, body mass index (BMI), and systolic and diastolic blood pressure — all of which tend to increase with heavy drinking and pose such serious health risks as heart disease and cirrhosis. Notably, these combined effects suggest that topiramate may decrease the risk of heart disease in alcohol dependent individuals.

“These findings add growing data indicating that heavy drinkers who modify their drinking with the help of medication and supportive counseling may see an improvement in health and well-being, as well as a potential reduction of risk for the development of heart and liver diseases. This shows that treatment of alcoholism has potential health benefits beyond the immediate behavioral and emotional improvement caused by a reduction in drinking” said Raymond Anton, M.D., distinguished university professor.

By decreasing liver enzymes and cholesterol levels, topiramate also may reduce the risk of fatty liver disease, which leads to cirrhosis – a common consequence to end-stage liver disease leading to death in some alcoholics.

Additionally, topiramate significantly contributed to a decline in obsessive thoughts and compulsions, components of alcohol craving, and also had a greater improvement in their “overall quality of life,” and specifically an improvement in general and leisure activities and household duties, as well as a reduction in sleep disturbances.

The Food and Drug Administration has approved topiramate for seizures and migraine headaches, but it is not currently approved for treating alcohol dependence. Ortho-McNeil Neurologics, Inc., manufactures topiramate and provided study funding.

Results from the nationwide 14-week trial involving 371 male and female diagnosed alcoholics was published in the June 9 issue of the Archives of Internal Medicine.

In addition, Anton presented initial results from a separate investigation of a 14-week double-blind, placebo-controlled study utilizing the PROMETA ® alcoholism treatment program, developed by Hythiam, inc., at the 2008 Research Society on Alcoholism (RSA) conference in Washington D.C.

Anton suggested that alcohol dependence programs are few in number and not exceptionally effective, which is particularly true for individuals who experience alcohol withdrawal symptoms. PROMETA ®, a combination of generic medications, reduced cravings and alcohol withdrawal symptoms, promoted abstinence, and improved mood and sleep only in those who had symptoms of alcohol withdrawal. Although the PROMETA ® Protocol has been marketed nationally, this was the first scientific study examining its utility in individuals with alcohol dependence.

At the time of the RSA presentation, the data presented covered the initial six-week active treatment phase of the 14-week study. While these are initial findings, additional evaluation of the full 14-week study data is ongoing, and Anton plans to release these specifics in a peer-reviewed publication.

MUSC has an ongoing clinical trial program studying new medications for the treatment of alcohol use disorders. For more information call 843-792-2727.
__________
source: Newswise Medical News

More Treatment & Detox Articles

Fetal alcohol exposure affects teenage drinking behavior

According to scientists, there is a link between exposure to alcohol in the womb and an attraction to its smell during teenage life. The researchers state that a fetus can recall and be drawn to odor stimuli from what its mother ingests during pregnancy. A new study from the State University of New York found….

Continue reading

What Can Private Drug Treatment Do For Me?

Private Drug Treatment Program

If you are thinking about seeking help for your addiction to drugs or alcohol, you are probably questioning just about every aspect of the situation. If you’re considering private drug or alcohol treatment consider the following benefits of seeking treatment in a private treatment center versus a public facility that provides care. Private treatment centers….

Continue reading

Naltrexone: can a pill cure alcoholism?

Naltrexone is cheap, effective and requires no costly rehab. So why do so few doctors endorse it? Mrs M, as she asks me to call her, isn’t sure exactly when she last drank herself into a comatose state, but she knows it was about five years ago. At that time she got through a bottle….

Continue reading

Abstinence the path to avoid alcoholism

Parents throughout Victoria and Canada are vehemently opposed to their children taking illicit drugs — but what about the most widely used, and deadliest drug of all? There is a killer that lives among us every day — a killer called alcohol. In recent years, it has been common practice for parents to condone underage….

Continue reading